Veeva Systems (NYSE:VEEV – Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 7.320-7.320 for the period, compared to the consensus earnings per share estimate of 6.970. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.1 billion. Veeva Systems also updated its Q1 2026 guidance to 1.740-1.750 EPS.
Analyst Upgrades and Downgrades
VEEV has been the topic of several recent analyst reports. KeyCorp dropped their price target on Veeva Systems from $285.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. The Goldman Sachs Group downgraded shares of Veeva Systems from a “buy” rating to a “sell” rating and dropped their target price for the company from $261.00 to $200.00 in a research report on Thursday, January 23rd. Citigroup lifted their price target on shares of Veeva Systems from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Stifel Nicolaus raised their target price on Veeva Systems from $240.00 to $272.00 and gave the company a “buy” rating in a research note on Friday, December 6th. Finally, Bank of America upped their price target on Veeva Systems from $280.00 to $290.00 and gave the stock a “neutral” rating in a research note on Friday, December 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average price target of $255.28.
Read Our Latest Stock Analysis on Veeva Systems
Veeva Systems Stock Up 7.5 %
About Veeva Systems
Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.
Featured Stories
- Five stocks we like better than Veeva Systems
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?
- The How And Why of Investing in Oil Stocks
- These 3 Big Banks Are Set to Gain as Consumers Stash More Cash
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Wall Street Says Chipotle Has 30% Upside—Should You Bite?
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.